El Salvador
Tuberculosis profile
Population  2012 6.3 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.065 (0.046–0.088) 1 (0.73–1.4)
Mortality (HIV+TB only) 0.018 (0.015–0.027) 0.28 (0.23–0.43)
Prevalence  (includes HIV+TB) 2.2 (0.77–4.3) 34 (12–68)
Incidence  (includes HIV+TB) 1.6 (1.4–1.8) 25 (22–29)
Incidence (HIV+TB only) 0.2 (0.17–0.23) 3.2 (2.7–3.7)
Case detection, all forms (%) 130 (110–150)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 1 237 (63) Relapse 88 (90)
Smear-negative 313 (16) Treatment after failure 5 (5)
Smear-unknown / not done 0 (0) Treatment after default 5 (5)
Extrapulmonary 415 (21) Other 0 (0)
Other 0 (0)      
Total new 1 965   Total retreatment 98  
           
Other (history unknown) 0        
Total new and relapse 2 053   Total cases notified 2 063  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.6 1.5 1.5
Age < 15 10 177 48
Laboratories 2012
Smear (per 100 000 population) 3.3
Culture (per 5 million population) 8.7
Drug susceptibility testing (per 5 million population) 0.8
Is second-line drug susceptibility testing available? Yes, outside
country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 93   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 92  
Retreatment 90  
TB/HIV 2012 Number (%)
TB patients with known HIV status 2 036 (99)
HIV-positive TB patients 214 (11)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 142 (66)
HIV-positive TB patients on antiretroviral therapy (ART) 178 (83)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 0.33 (0.04–1.2) 11 (4.9–20)
MDR-TB cases among notified pulmonary
TB cases
5 (1–18) 11 (5–20)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 252 (20%) 73 (74%) 325
Laboratory-confirmed MDR-TB cases 0 8 8
Patients started on MDR-TB treatment     10
Financing TB control 2013
National TB programme budget (US$ millions) 7.1
% Funded domestically 55%
% Funded internationally 20%
% Unfunded 24%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-16 Data: www.who.int/tb/data